79 Results for "

glucose-dependent

" in MedChemExpress (MCE) Product Catalog:
Products (79)

79 Results for "glucose-dependent" in MCE Product Catalog:

42
42 Publications Verification
Cat. No.: HY-P0014B
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
loading...
    loading...
31
31 Cited Publications
Cat. No.: HY-13749
CAS No.: 486460-32-6
Purity:  99.75%
Synonyms: MK-0431
Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes .
loading...
    loading...
31
31 Cited Publications
Cat. No.: HY-13749A
CAS No.: 654671-78-0
Purity:  99.79%
Synonyms: MK-0431 phosphate
Sitagliptin (MK-0431) phosphate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes .
loading...
    loading...
31
31 Cited Publications
Cat. No.: HY-13749B
CAS No.: 654671-77-9
Purity:  99.83%
Synonyms: MK-0431 phosphate monohydrate
Sitagliptin (MK-0431) phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-135897
CAS No.: 165393-06-6
Purity:  ≥98.0%
Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of insulin secretion. Urolithin C is a L-type Ca 2+ channel opener and enhances Ca 2+ influx. Urolithin C induces cell apoptosis through a mitochondria-mediated pathway and also stimulates reactive oxygen species (ROS) formation .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P3506
CAS No.: 2381089-83-2
Synonyms: LY3437943
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease

Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P10138
CAS No.: 1884226-05-4
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide has potential anti-obesity and anti-diabetic effects .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P3506A
Synonyms: LY3437943 TFA
Target:  

GLP Receptor GCGR

Research Areas:  

Metabolic Disease

Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P10138A
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

Human GIP(3-30), amide TFA is the TFA salt form of human GIP(3-30), amide (HY-P10138). Human GIP(3-30), amide TFA is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide TFA has potential anti-obesity and anti-diabetic effects .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13967B
CAS No.: 1259389-38-2
Purity:  99.00%
Research Areas:  

Metabolic Disease

AMG 837 calcium hydrate is an orally active, selective GPR40/FFA1 agonist with an EC50 of 1.5 nM against human GPR40. AMG 837 calcium hydrate stimulates insulin secretion in a glucose-dependent manner, and effectively improves glycemic control in both normal and diabetic rodent models . AMG 837 calcium hydrate binds to the BacA protein and impairs the survival and replication of Brucella. AMG 837 calcium hydrate can be used in research related to type 2 diabetes and brucellosis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P3506B
Synonyms: LY3437943 acetate
Target:  

GCGR GLP Receptor

Research Areas:  

Metabolic Disease

Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13967
CAS No.: 865231-46-5
AMG 837 is an orally active, selective GPR40/FFA1 agonist with an EC50 of 1.5 nM against human GPR40. AMG 837 stimulates insulin secretion in a glucose-dependent manner, and effectively improves glycemic control in both normal and diabetic rodent models . AMG 837 binds to the BacA protein and impairs the survival and replication of Brucella. AMG 837 can be used in research related to type 2 diabetes and brucellosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P0276
CAS No.: 100040-31-1
Synonyms: Gastric Inhibitory Peptide (GIP), human
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P0276A
Synonyms: Gastric Inhibitory Peptide (GIP), human TFA
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P2080B
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10 -9-10 -6 M .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P2541A
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107535
CAS No.: 330981-72-1
Purity:  99.84%
Target:  

GPR119 TRP Channel

Research Areas:  

Metabolic Disease

AS1269574 is a potent, orally available GPR119 agonist, with an EC50 of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-164535
CAS No.: 2887445-76-1
Synonyms: AMG 133
Maridebart cafraglutide (AMG 133) is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonist with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. Maridebart cafraglutide shows antagonist activity against human, cynomolgus monkey and rat GIPR with IC50 values of 46.4 nM, 26.5 nM, 822.3 nM, respectively. Maridebart cafraglutide shows agonist activity against human, cynomolgus monkey, rat and mouse GLP-1R with EC50 values of 24.4 pM, 5.7 pM, 2.4 pM and 123 pM, respectively. Maridebart cafraglutide can be used for the study of obesity and type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P2542
CAS No.: 1802086-25-4
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo .
loading...
    loading...
Cat. No.: HY-N0466
CAS No.: 58543-16-1
Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC50 value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity .
loading...
    loading...